Drospirenone; Ethinyl Estradiol; Levomefolate Calcium Patent Expiration
Drospirenone; Ethinyl Estradiol; Levomefolate Calcium is Used for contraception, prevention of pregnancy, and treating mood changes and anxiety in women with PMDD who choose oral contraceptives. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Drospirenone; Ethinyl Estradiol; Levomefolate Calcium Patents
Given below is the list of patents protecting Drospirenone; Ethinyl Estradiol; Levomefolate Calcium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Beyaz | US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid | Jul 17, 2030 | Bayer Hlthcare |
| Beyaz | US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul 10, 2015
(Expired) | Bayer Hlthcare |
| Beyaz | US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Apr 17, 2020
(Expired) | Bayer Hlthcare |
| Beyaz | US6958326 | Cyclodextrin-drospirenone inclusion complexes |
Dec 30, 2021
(Expired) | Bayer Hlthcare |
| Beyaz | US7163931 | Compositions of estrogen-cyclodextrin complexes |
Mar 03, 2022
(Expired) | Bayer Hlthcare |
| Beyaz | US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid | Feb 08, 2030 | Bayer Hlthcare |
| Beyaz | USRE37564 | Composition for contraception |
Jun 30, 2014
(Expired) | Bayer Hlthcare |
| Beyaz | USRE37838 | Composition for contraception |
Jun 30, 2014
(Expired) | Bayer Hlthcare |
| Beyaz | USRE38253 | Composition for contraception |
Jun 30, 2014
(Expired) | Bayer Hlthcare |
| Beyaz | USRE43916 | Composition for contraception |
Jun 30, 2014
(Expired) | Bayer Hlthcare |
| Safyral | US11617751 | Pharmaceutical composition containing a tetrahydrofolic acid | Jul 17, 2030 | Bayer Hlthcare |
| Safyral | US5798338 | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul 10, 2015
(Expired) | Bayer Hlthcare |
| Safyral | US6441168 | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Apr 17, 2020
(Expired) | Bayer Hlthcare |
| Safyral | US6958326 | Cyclodextrin-drospirenone inclusion complexes |
Dec 20, 2021
(Expired) | Bayer Hlthcare |
| Safyral | US7163931 | Compositions of estrogen-cyclodextrin complexes |
Mar 03, 2022
(Expired) | Bayer Hlthcare |
| Safyral | US8617597 | Pharmaceutical composition containing a tetrahydrofolic acid | Feb 08, 2030 | Bayer Hlthcare |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Drospirenone; Ethinyl Estradiol; Levomefolate Calcium Generics
Several generic applications have been filed for Drospirenone; Ethinyl Estradiol; Levomefolate Calcium. The first generic version for Drospirenone; Ethinyl Estradiol; Levomefolate Calcium was by Watson Laboratories Inc and was approved on Oct 11, 2016. And the latest generic version is by Lupin Ltd and was approved on Jun 13, 2018.
Given below is the list of companies who have filed for Drospirenone; Ethinyl Estradiol; Levomefolate Calcium generic.
1. LUPIN LTD
Lupin Ltd has filed for 2 different strengths of generic version for Drospirenone; Ethinyl Estradiol; Levomefolate Calcium. Out of these 3mg,n/a;0.03mg,n/a;0.451mg,0.451mg version comes by the name TYDEMY, 3mg,n/a;0.02mg,n/a;0.451mg,0.451mg version comes by the name DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM. Given below are the details of the strengths of this generic introduced by Lupin Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3MG,N/A; 0.03MG,N/A; 0.451MG,0.451MG | tablet | Prescription | ORAL | AB | Dec 12, 2017 |
| 3MG,N/A; 0.02MG,N/A; 0.451MG,0.451MG | tablet | Prescription | ORAL | AB | Jun 13, 2018 |
2. WATSON LABS INC
Watson Laboratories Inc has filed for 2 different strengths of generic version for Drospirenone; Ethinyl Estradiol; Levomefolate Calcium. All of these versions come by the name DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM. Given below are the details of the strengths of this generic introduced by Watson Labs Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 3MG,N/A; 0.02MG,N/A; 0.451MG,0.451MG | tablet | Prescription | ORAL | AB | Oct 11, 2016 |
| 3MG,N/A; 0.03MG,N/A; 0.451MG,0.451MG | tablet | Prescription | ORAL | AB | Oct 11, 2016 |